An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection
Source abstract
Abstract
The surge of fast-spreading SARS-CoV-2 mutated variants highlights the need for fast, broad-spectrum strategies to counteract viral infections. In this work, we report a physical barrier against SARS-CoV-2 infection based on an inhalable bioadhesive hydrogel, named spherical hydrogel inhalation for enhanced lung defence (SHIELD). Conveniently delivered via a dry powder inhaler, SHIELD particles form a dense hydrogel network that coats the airway, enhancing the diffusional barrier properties and restricting virus penetration. SHIELD's protective effect is first demonstrated in mice against two SARS-CoV-2 pseudo-viruses with different mutated spike proteins. Strikingly, in African green monkeys, a single SHIELD inhalation provides protection for up to 8 hours, efficiently reducing infection by the SARS-CoV-2 WA1 and B.1.617.2 (Delta) variants. Notably, SHIELD is made with food-grade materials and does not affect normal respiratory functions. This approach could offer additional protection to the population against SARS-CoV-2 and other respiratory pathogens.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · COVID-19 diagnosis using AI
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Johns Hopkins University & Medicine, Coronavirus Resource Center, https://coronavirus.jhu.edu/(2023).
2. Burki, T. Understanding variants of SARS-CoV-2. Lancet 397, 462 (2021).10.1016/S0140-6736(21)00298-1 ↗
3. Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021).10.1038/s41586-021-03402-9 ↗
4. Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020).10.1038/s41586-020-2798-3 ↗
5. Creech, C. B., Walker, S. C. & Samuels, R. J. SARS-CoV-2 vaccines. JAMA 325, 1318–1320 (2021).10.1001/jama.2021.3199 ↗
6. Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021).10.1038/s41586-021-03777-9 ↗
7. Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116–121 (2021).10.1038/s41586-020-2895-3 ↗
8. Tang, S. et al. Aerosol transmission of SARS-CoV-2? Evidence, prevention and control. Environ. Int. 144, 106039 (2020).10.1016/j.envint.2020.106039 ↗
9. Harrison, A. G., Lin, T. & Wang, P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 41, 1100–1115 (2020).10.1016/j.it.2020.10.004 ↗
10. Hou, Y. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464–1468 (2020).10.1126/science.abe8499 ↗
11. Wanner, A., Salathé, M. & O’Riordan, T. G. Mucociliary clearance in the airways. Am. J. Respir. Crit. Care Med. 154, 1868–1902 (1996).10.1164/ajrccm.154.6.8970383 ↗
12. Fahy, J. V. & Dickey, B. F. Airway mucus function and dysfunction. N. Engl. J. Med. 363, 2233–2247 (2010).10.1056/NEJMra0910061 ↗
13. Antunes, M. B., Gudis, D. A. & Cohen, N. A. Epithelium, cilia, and mucus: their importance in chronic rhinosinusitis. Immunol. Allergy Clin. 29, 631–643 (2009).
14. Ganesan, S., Comstock, A. T. & Sajjan, U. S. Barrier function of airway tract epithelium. Tissue Barriers 1, e24997 (2013).10.4161/tisb.24997 ↗
15. Randell, S. H. & Boucher, R. C. Effective mucus clearance is essential for respiratory health. Am. J. Respir. Cell Mol. 35, 20–28 (2006).10.1165/rcmb.2006-0082SF ↗
16. Marjolaine, V., Elisabeth, K., Edwards, M. E. & Nicolas, R. The airway epithelium: soldier in the fight against respiratory viruses. Clin. Microbiol. Rev. 24, 210–229 (2011).10.1128/CMR.00014-10 ↗
17. Zhu, N. et al. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat. Commun. 11, 3910 (2020).
18. Brann, D. et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci. Adv. 6, eabc5801 (2020).10.1126/sciadv.abc5801 ↗
19. Parhi, R. Drug delivery applications of chitin and chitosan: a review. Environ. Chem. Lett. 18, 577–594 (2020).10.1007/s10311-020-00963-5 ↗
20. Yuk, H. et al. Dry double-sided tape for adhesion of wet tissues and devices. Nature 575, 169–174 (2019).10.1038/s41586-019-1710-5 ↗
21. Yuk, H. et al. Tough bonding of hydrogels to diverse non-porous surfaces. Nat. Mater. 15, 190–196 (2016).10.1038/nmat4463 ↗
22. Deng, J. et al. Electrical bioadhesive interface for bioelectronics. Nat. Mater. 20, 229–236 (2021).10.1038/s41563-020-00814-2 ↗
23. Mao, X., Yuk, H. & Zhao, X. Hydration and swelling of dry polymers for wet adhesion. J. Mech. Phys. Solids 137, 103863 (2020).10.1016/j.jmps.2020.103863 ↗
24. Wu, J. et al. An off-the-shelf bioadhesive patch for sutureless repair of gastrointestinal defects. Sci. Transl. Med. 14, eabh2857 (2022).10.1126/scitranslmed.abh2857 ↗
25. Yuan, S. et al. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels. Sci. Transl. Med. 7, 276ra27 (2015).10.1126/scitranslmed.3010525 ↗
26. Djaković, S. et al. 1′-Acetylferrocene amino acid esters and amides. A simple model for parallel β-helical peptides. Tetrahedron 70, 2330–2342 (2014).10.1016/j.tet.2014.02.047 ↗
27. Kootala, S. et al. Reinforcing mucus barrier properties with low molar mass chitosans. Biomacromolecules 19, 872–882 (2018).10.1021/acs.biomac.7b01670 ↗
28. Pelaseyed, T. et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol. Rev. 260, 8–20 (2014).10.1111/imr.12182 ↗
29. Muñoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509–515 (2020).10.1038/s41586-020-2787-6 ↗
30. Rahman, C. K., Sharun, K., Jose, B., Sivaprasad, M. S. & Jisna, K. S. Animal models for SARS-CoV-2 infection: a tool for vaccine and therapeutic research. Trends Biomater. Artif. Organs 34, 78–82 (2020).
31. Albrecht, L. et al. COVID-19 research: lessons from non-human primate models. Vaccines 9, 886 (2021).10.3390/vaccines9080886 ↗
32. Bi, Z., Hong, W., Yang, J., Lu, S. & Peng, X. Animal models for SARS-CoV-2 infection and pathology. MedComm 2, 548–568 (2021).10.1002/mco2.98 ↗
33. Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369, 818–823 (2020).10.1126/science.abc5343 ↗
34. Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020).10.1038/s41586-020-2381-y ↗
35. Hemmat, N. et al. The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV. Arch. Virol. 166, 675–696 (2021).10.1007/s00705-021-04958-7 ↗
36. Johnston, S. C. et al. Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure. PLoS One 16, e0246366 (2021).10.1371/journal.pone.0246366 ↗
37. Liu, L. et al. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).10.1172/jci.insight.123158 ↗
38. Carlson, T. L., Lock, J. Y. & Carrier, R. L. Engineering the mucus barrier. Annu. Rev. Biomed. Eng. 20, 197–220 (2018).10.1146/annurev-bioeng-062117-121156 ↗
39. Schiller, J. L. & Lai, S. K. Tuning barrier properties of biological hydrogels. ACS Appl. Bio. Mater. 3, 2875–2890 (2020).10.1021/acsabm.0c00187 ↗
40. Lieleg, O., Lieleg, C., Bloom, J., Buck, C. B. & Ribbeck, K. Mucin biopolymers as broad-spectrum antiviral agents. Biomacromolecules 13, 1724–1732 (2012).10.1021/bm3001292 ↗
41. Janssen, W. J., Stefanski, A. L., Bochner, B. S. & Evans, C. M. Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions. Eur. Respir. J. 48, 1201–1214 (2016).10.1183/13993003.00120-2015 ↗
42. Lee, IvanT. et al. ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. Nat. Commun. 11, 5453 (2020).10.1038/s41467-020-19145-6 ↗
43. Kurakula, M., Gorityala, S. & Moharir, K. Recent trends in design and evaluation of chitosan-based colon targeted drug delivery systems: update 2020. J. Drug Deliv. Sci. Technol. 64, 102579 (2021).10.1016/j.jddst.2021.102579 ↗
44. Hamedi, H., Moradi, S., Hudson, S. M., Tonelli, A. E. & King, M. W. Chitosan based bioadhesives for biomedical applications: a review. Carbohydr. Polym. 282, 119100 (2022).10.1016/j.carbpol.2022.119100 ↗
45. Davies, H. S. et al. Reorganisation of the salivary mucin network by dietary components: insights from green tea polyphenols. PLoS One 9, e108372 (2014).10.1371/journal.pone.0108372 ↗
46. Hanafy, N. A. N., Leporatti, S. & El-Kemary, M. A. Mucoadhesive hydrogel nanoparticles as smart biomedical drug delivery system. Appl. Sci. 9, 825–836 (2019).10.3390/app9050825 ↗
47. Scaldaferri, F., Pizzoferrato, M., Gerardi, V., Lopetuso, L. & Gasbarrini, A. The gut barrier: new acquisitions and therapeutic approaches. J. Clin. Gastroenterol. 46, 12–17 (2012).10.1097/MCG.0b013e31826ae849 ↗
48. Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827 (2020).10.1016/j.cell.2020.06.043 ↗
49. Grubaugh, N. D., Hanage, W. P. & Rasmussen, A. L. Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear. Cell 182, 794–795 (2020).10.1016/j.cell.2020.06.040 ↗
50. Alina, B. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018 (2020).10.1126/science.abd0831 ↗
51. Ning, B., Huang, Z. & Youngquist, B.M. et al. Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma. Nat. Nanotechnol. 16, 1039–1044 (2021).10.1038/s41565-021-00939-8 ↗
52. Furukawa, H., Inaba, H. & Inoue, F. et al. Enveloped artificial viral capsids self-assembled from anionic β-annulus peptide and cationic lipid bilayer. Chem. Commun 56, 7092–7095 (2020).10.1039/D0CC02622K ↗
53. Kong, H., Liu, J. & Riddle, K. et al. Non-viral gene delivery regulated by stiffness of cell adhesion substrates. Nat. Mater. 4, 460–464 (2005).10.1038/nmat1392 ↗
54. McCarty, K.S., Miller, L.S., Cox, E.B., Konrath, J. & McCarty KS, S. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Path. Lab 109, 716–721 (1985).
55. McCarty, K.S., Szabo, E. & Flowers, J.L. et al. Use of a monoclonal antiestrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 46, 4244–4248 (1986).
56. Cha, Y.J., Lee, J.S. & Kim, H.R. et al. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS One 9, e103333 (2014).10.1371/journal.pone.0103333 ↗
57. Yoshida, A., Tsuta, K. & Wakai, S. et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol. 27, 711–720 (2014).10.1038/modpathol.2013.192 ↗